Advanced Medical Solutions Grp PLC Pre-Close Trading Update (0356J)
December 15 2015 - 2:00AM
UK Regulatory
TIDMAMS
RNS Number : 0356J
Advanced Medical Solutions Grp PLC
15 December 2015
15 December 2015
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Pre-Close Trading Update
Winsford, UK, 15 December: Advanced Medical Solutions Group plc
(AIM: AMS.L), the surgical and advanced wound care specialist
company, today announces an update on trading prior to its close
period for the year ending 31 December 2015.
The Group continues to make good progress, as highlighted in the
2015 Interim Results announcement on 9 September 2015, and, despite
revenue being impacted by currency, the Board expects both revenue
and profitability to be in line with current market expectations
for the full year 2015.
The regulatory approvals that AMS has received this year for its
new antimicrobial foams, together with the clearance to market its
sutures in the US, have not had an impact on the 2015 results but
are expected to contribute to growth in 2016.
Chris Meredith, Chief Executive Officer of AMS, said: "The Group
continues to deliver strong organic growth supported by a pipeline
of new products coming out of our Research and Development teams.
We are confident that AMS is very well positioned to deliver
further growth."
The Group expects to publish its Preliminary Results for the
year to 31 December 2015 in March 2016.
Following the publication of FRS 100 Application of Financial
Reporting Requirements by the Financial Reporting Council, Advanced
Medical Solutions Group plc is required to change its accounting
framework for its entity financial statements, which is currently
UK GAAP, for its financial year commencing 1 January 2015. The
Board considers that it is in the best interest of Advanced Medical
Solution Group plc to adopt FRS101 Reduced Disclosure Framework for
its Parent Company financial statements, for the year ended 31
December 2015. The group financial statements will continue under
International Financial Reporting Standards (IFRS)
A shareholder or shareholders may serve objections to the use of
the disclosure exemptions on Advanced Medical Solution Group plc,
in writing, to its registered office at Premier Park, 33 Road One,
Winsford Industrial Estate, Cheshire CW7 3RT not later than 31
December 2015.
- Ends -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606 545508
--------------------------------------------------------------- -------------------------
Chris Meredith, Chief Executive Officer
Mary Tavener, Group Finance Director
--------------------------------------------------------------- -------------------------
Consilium Strategic Communications Tel: +44 (0) 3709 5702
--------------------------------------------------------------- -------------------------
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys
--------------------------------------------------------------- -------------------------
Investec Bank plc (NOMAD & Broker) Tel: +44 (0) 20 7597 5970
--------------------------------------------------------------- -------------------------
Gary Clarence / Daniel Adams / Patrick Robb
--------------------------------------------------------------- -------------------------
About Advanced Medical Solutions Group plc - see
www.admedsol.com
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical, wound care and wound closure markets, focused on quality
outcomes for patients and value for payors. AMS has a wide range of
products that include silver alginates, alginates, foams, tissue
adhesives, sutures and haemostats, which it markets under its
brands ActivHeal(R) , LiquiBand(R) and RESORBA(R) as well as
supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in
the Netherlands, two in Germany and one in the Czech Republic, are
sold in 65 countries via a network of multinational or regional
partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia.
Established in 1991, the Group has approximately 470 employees.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLFFSLFFLSLIE
(END) Dow Jones Newswires
December 15, 2015 02:00 ET (07:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2023 to Apr 2024
